The case for psilocybin in treatment-resistant depression rests on a real signal: a rapid and in some patients durable antidepressant effect following one or two supervised sessions, at doses that don't produce physical dependence, in patients who have failed multiple prior treatments. The Phase 2b COMP360 trial published in NEJM showed that 25mg psilocybin produced a significant reduction in depression scores at week 3 versus 1mg (a comparator that produces perceptual effects too mild to constitute a genuine active control — which is itself a problem we need to discuss). The story of psychedelic therapy in 2026 is a story about genuinely promising data that has to navigate genuinely difficult clinical trial design challenges before it becomes approved medicine.
This article is for informational purposes only. Psilocybin remains a Schedule I substance in the US and is not an approved medicine outside of clinical trial settings and limited state programs. Do not attempt self-administration. If you have treatment-resistant depression, speak with a psychiatrist about clinical trial options.
Summary
COMPASS Pathways' COMP360 Phase 2b showed 25mg psilocybin significantly reduced MADRS depression score at week 3 in treatment-resistant depression (TRD) — with 29.1% of patients achieving response and 24.1% in remission, versus 7.6% and 10.1% for 1mg. The 3-month durability was partial: a proportion of responders relapsed. FDA has granted Breakthrough Therapy designation for psilocybin for TRD. USONA Institute's PSIL201 for MDD received separate Breakthrough designation. MAPS' MDMA Phase 3 for PTSD hit controversy at FDA advisory committee level (committee voted 9-2 against approval in June 2024) primarily over functional unblinding and functional outcomes concerns. As of 2026, no psychedelic therapy is FDA-approved; multiple Phase 3 trials are underway. Australia approved psilocybin and MDMA therapy through the TGA in 2023.
ClinicalMetric Analysis
- The blinding problem in psychedelic trials is a genuine methodological challenge, not a rhetorical one. Psilocybin at therapeutic doses produces a distinctive subjective experience that essentially all participants recognize as active treatment. The 1mg or 0.1mg "control" doses used in several trials do produce mild effects, but functional unblinding — where participants know whether they received active drug — likely exceeds 90%. This is not unique to psychedelics (stimulants, opioids, and ketamine all have this problem), but it matters particularly for subjective outcome measures like depression rating scales, where expectancy effects are large. The FDA's pushback on MDMA was partly about this. The solution — an active control producing similar subjective effects without antidepressant activity — doesn't cleanly exist. Niacin, methamphetamine microdose, and inactive placebo have all been tried with unsatisfactory results. This blinding problem will follow the field through every Phase 3 trial.
- The psychotherapy bundled with psilocybin is an active ingredient, and it's not standardized. Virtually all psilocybin trials include preparatory sessions, session-day psychological support (therapist present during the psilocybin experience), and integration sessions afterward. The totality of this psychotherapy — therapist training, session structure, the model of care — likely contributes to outcomes. But it varies across trials and sites, it's hard to manualize, and it can't be separated from the drug in a way that tells you how much work each component is doing. When and if psilocybin is approved, the question of what psychotherapy model it must be paired with (and how to train and certify the therapists) is a major implementation challenge that the trials don't resolve.
- The durability of response after a single psilocybin session is probably months, not years — and that changes the treatment model. The romantically appealing narrative of psychedelic therapy is a one-time experience with permanent benefit. The COMP360 data doesn't support this: at week 12, only about 20% of the 25mg responders maintained remission. Johns Hopkins data shows similar patterns — meaningful benefit for a proportion of patients, with durability varying substantially. This means psilocybin therapy, if approved, would likely become a periodic intervention (every 6–12 months) rather than a one-time cure — with implications for the cost model, the therapist capacity required, and the healthcare system's ability to deliver it at scale.
COMP360 Phase 2b: What the Data Showed
COMPASS Pathways conducted a double-blind, randomized, dose-finding Phase 2b trial (NCT03523976) across 22 sites in 10 countries. 233 patients with TRD (failed at least 2 adequate antidepressant trials) received a single dose of COMP360 psilocybin at 25mg, 10mg, or 1mg, with psychological support from trained therapists.
Primary endpoint: change from baseline in MADRS (Montgomery–Åsberg Depression Rating Scale) score at week 3. Results: 25mg group showed a least-squares mean change of -14.9 points versus -6.6 points for 1mg (difference -8.3, 95% CI -12.2 to -4.4, p<0.001). The 10mg group was not significantly different from 1mg (-12.2 points, p=0.18). Response at week 3 (≥50% reduction from baseline): 29.1% for 25mg, 9.4% for 10mg, 7.6% for 1mg. Remission (MADRS ≤10): 24.1% for 25mg vs 10.1% for 1mg.
Safety findings: 12 participants in the 25mg group had serious adverse events (mostly related to suicidal ideation in a TRD population — not surprising but requiring careful monitoring). Transient adverse effects: headache, nausea, dizziness during the session day, all resolved. No adverse cardiac events or serious physical harm.
MDMA for PTSD: Why FDA Said No
MAPS (Multidisciplinary Association for Psychedelic Studies) submitted a New Drug Application for MDMA-assisted therapy for PTSD in 2023, following Phase 3 MAPP1 and MAPP2 trials showing significant symptom reduction versus placebo on the CAPS-5 scale. The FDA's advisory committee voted 9-2 against approval in June 2024, citing: functional unblinding as a systematic source of bias in subjective outcomes; concerns about functional outcomes data (employment, relationships) that showed less consistent improvement; data integrity concerns at some sites; and the complexity of the bundled therapy model making it difficult to characterize what was being approved.
The FDA ultimately issued a complete response letter (rejection). MAPS has committed to additional trials addressing the committee's concerns. The MDMA setback has influenced how psilocybin sponsors are designing their Phase 3 trials — greater emphasis on objective biomarkers alongside subjective scales, more rigorous site training, and cleaner functional outcomes measures.
The Broader Pipeline: Beyond Depression and PTSD
The psychedelic trial pipeline in 2026 extends to several indications. Alcohol use disorder (AUD): NYU and Johns Hopkins randomized trials have shown psilocybin significantly reduces alcohol consumption versus diphenhydramine control (12 weeks: 83% reduction in heavy drinking days vs 51%; JAMA Psychiatry 2022). AWAKENED study (NYU, 100 participants) extending this work. Major depressive disorder (not just TRD): USONA PSIL201 Phase 2/3, COMPASS Phase 3 (COMP360-TRD). Anorexia nervosa: COMPASS Phase 2 (COMP360-AN); eating disorders represent a high unmet need population. End-of-life existential distress: Johns Hopkins/NYU studies show robust and durable reduction in cancer-related depression and death anxiety after psilocybin — perhaps the most consistent findings in the entire literature. Smoking cessation: Johns Hopkins 80% abstinence at 6-month follow-up in a small pilot (n=15) — unprecedentedly high rate compared to standard pharmacotherapy — now in a larger RCT.
Participating in a Psilocybin Trial
Most psilocybin trials enroll adults 18–65 with a confirmed diagnosis of TRD, MDD, AUD, or PTSD depending on the trial. Common exclusions: personal or first-degree family history of psychosis, bipolar I disorder, active suicidal ideation with intent or plan, lithium use (risk of serotonin toxicity), SSRIs at full therapeutic dose (protocols vary on washout requirements). Most trials require psychiatric stabilization before enrollment and have active safety monitoring protocols including next-day check-ins. Sites conducting psilocybin trials are typically academic psychiatry centers. ClinicalTrials.gov search terms: "psilocybin," "COMP360," "PSIL201."